A novel mitochondrial DNA deletion in a patient with Kearns-Sayre syndrome: a late-onset of the fatal cardiac conduction deficit and cardiomyopathy accompanying long-term rGH treatment by Monika Obara-Moszynska et al.
Obara-Moszynska et al. BMC Pediatrics 2013, 13:27
http://www.biomedcentral.com/1471-2431/13/27CASE REPORT Open AccessA novel mitochondrial DNA deletion in a patient
with Kearns-Sayre syndrome: a late-onset of the
fatal cardiac conduction deficit and
cardiomyopathy accompanying long-term rGH
treatment
Monika Obara-Moszynska1*, Jaroslaw Maceluch1, Waldemar Bobkowski2, Artur Baszko3, Oskar Jaremba2,
Maciej R Krawczynski4 and Marek Niedziela1Abstract
Background: Kearns-Sayre Syndrome (KSS) is a multisystem disorder caused by a dysfunction of the oxidative
phosphorylation system within mitochondria. Mitochondrial DNA (mtDNA) rearrangements are a key molecular
feature of this disease, which manifest a broad phenotypic spectrum.
Case presentation: Here, we present a boy with KSS whose symptoms included cardiac conduction deficit,
cardiomyopathy and growth hormone (GH) deficiency. The patient showed typical symptoms for KSS from early
childhood (chronic progressive external ophthalmoplegia, retinopathy, short stature). Long-range PCR analysis
disclosed a 7663-base pair heteroplasmic deletion in the mtDNA encompassing nucleotides 6340–14003. At
12 years of age, GH deficiency was recognized and recombinant growth hormone (rGH) therapy was started. At
15 years of age, a complete atrioventicular block was diagnosed and the patient received a pacemaker. During the
following 6 months, progressive deterioration of the left ventricle was observed and an echocardiogram showed
features of dilated cardiomyopathy. The rGH treatment was then discontinued at a final height of 163 cm.
Unfortunately, due to multi-organ insufficiency and inflammation, the patient died at the age of 18 years.
Conclusions: The response to rGH therapy in the patient was very satisfactory. The large mtDNA deletion had no
apparent impact on the response to rGH. Cardiac disturbances occurred as part of the syndrome and were not
related to rGH therapy; however, the progression of the disease led to death.
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statureBackground
Kearns-Sayre Syndrome (KSS) is a rare metabolic dis-
order which belongs to the group of mitochondrial
cytopathies [1]. The diagnosis of KSS is made based on
the classic triad of symptoms: onset of the disease before
20 years of age, progressive external ophthalmoplegia
(PEO) and pigmentary retinopathy (PR) [2]. KSS is* Correspondence: m.moszynska@ump.edu.pl
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distribution, and reproduction in any mediummanifested also by other systemic abnormalities: cardiac
conduction defects, different neurological abnormalities
and several endocrine disorders [3]. Progression of the
clinical symptoms in KSS usually lead to death before the
age of 30. Spontaneous mitochondrial DNA (mtDNA)
rearrangements underlie this disease. A variety of deletions
and/or duplications in mtDNA, affecting genes encoding
respiratory chain proteins, are found in most cases [4-6].
This leads to defects in energy production by mitochon-
dria and dysfunction of many tissues. This is particularly
noticeable in tissues with a high energy demand - likeed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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with normal molecules (heteroplasmy) and the propor-
tion of mutated to normal mtDNA correlates with the
severity of clinical symptoms. There is no effective
treatment for KSS and the complicated character of
clinical features can impede the establishment of the
correct diagnosis [1].
In this report we present the comprehensive clinical
diagnosis of KSS in a young male. The patient was ini-
tially hospitalized based on neurological symptoms,
followed by a diagnosis of his endocrinopathies. The
most serious features of the disease - a cardiac conduc-
tion deficit and cardiomyopathy developed some years
later. The final diagnosis was made several years after
the first symptoms appeared, and was established using
molecular biology techniques.Figure 1 Growth chart with patient growth pattern.Case presentation
The presented patient is an 18-year-old boy with
Kearns-Sayre Syndrome coexisting with GH deficiency,
complicated by a cardiac conduction deficit and
cardiomyopathy.
The child was adopted in early childhood and the family
history is unknown. The delivery was at term and uncom-
plicated. The boy was born small for gestational age with a
birth weight of 2500 g (−2,43 SD) and Apgar score of 10
points. From the second year of life, chronic progressive ex-
ternal ophthalmoplegia (CPEO) was observed. It started
with unilateral ptosis (left eye), which gradually progressed
to bilateral at 11 years of age. Additionally, extra-ocular
muscle palsy and pigmentary retinopathy (PR) were
observed. From early childhood, the boy displayed short
stature by relative normal body weight (Figure 1, Figure 2).
Figure 2 Growth chart with patient weight pattern.
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12 −3.5 10 8.5 161.9 0.024
after 6 months of rGH
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12 6/12 −2.9 11 10.5 164.6 0.024
after 12 months of rGH
therapy
13 −2.6 13 7.5 161.7 0.024
after 2 years of rGH
therapy
14 3/12 −2.2 13 6/12 10.0 168.5 0.022
after 3 years of rGH
therapy
15 2/12 −2.3 14 6/12 4.5 168.5 0.018
after 4 years of rGH
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16 −2.3 15 2.5 166.5 0.018
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treatment
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http://www.biomedcentral.com/1471-2431/13/27At the age of 11, he was admitted to the neurology
clinic. An electromyogram (EMG) was performed and
revealed a myogenic pattern. A magnetic resonance im-
aging (MRI) of the head showed hypoplasia of the pituitary
gland. Examination of cerebrospinal fluid, auditory evoked
potentials of the brainstem and electroencephalogram
(EEG) were all normal. Psychological examination identi-
fied an IQ at average level. The genetic analysis showed a
normal male (46,XY) karyotype.
Due to the clinical picture (CPEO, PR) and EMG
examination the diagnosis of Kearns-Sayre Syndrome
(KSS) was proposed.
Further endocrine work-up detected a partial growth
hormone deficiency. At 12 years of age, recombinant
growth hormone (rGH) therapy was started with a stand-
ard dose 0.025 mg/kg/day (Table 1). During rGH treat-
ment, the patient developed secondary hypothyroidism.Table 2 Levels of hormones and other biochemical paramete
Laboratory tests 10 yrs 12
Resul








IGF-1 (ng/ml) 212 428
max GH (after clonidine) (ng/ml) 4.3
max GH (after insulin) (ng/ml) 1.5
HbA1c (%) 5.9














CholesterolThe onset of puberty was spontaneous and initiated at
12 years and 3 months of age.
HbA1c levels were borderline when rGH treatment
was started and also 2 years later- they were 5.9% and
6.0% respectively (Table 2).
Further analysis revealed hyposecretion of insulin and
an elevated blood glucose in oral glucose tolerance test
(OGTT), glutamic acid decarboxylase (GAD), anti-insulin
(IAA) and insulinoma antigen 2 (IA2) antibodies were all
tested and were negative. Long acting insulin therapy was
started and rGH dose was reduced. The glucose concen-
tration then normalized. Insulin-like growth factor 1 (IGF-
1) levels during rGH administration were within the nor-
mal range, however, usually higher than the mean
expected for age and sex. Levels of hormones and other
biochemical parameters in blood samples are shown in
Table 2.rs in blood samples (abnormal values are given in bold)
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cardia was noticed. The patient displayed no major
complaints concerning the cardiovascular system and his
vital signs were all within normal limits - except for brady-
cardia. A detailed diagnostic work-up was ordered to deter-
mine the cause of the bradycardia. An electrocardiogram
(ECG) examination was also performed and confirmed an
intracardiac conduction abnormality characteristic of
complete atrio-ventricular block with slow regular ventricu-
lar escape rhythm (rate of 35–38 bpm) with wide QRS
complexes (Figure 3). The rate of the atrial rhythm was
80 bpm. As a next step, 24 h Holter monitoring was
performed which confirmed the presence of a complete
heart block, with minimum resting heart rate of 32 bpm,
maximum of 49 bpm and an average of 39 bpm. Echocar-
diogram examination was remarkable for mitral and tricus-
pid insufficiencies - both of second degree. The calculated
shortening fraction was 36%, with a left ventricular ejection
fraction value of 65%, good contractility was observed and
the dimensions of the heart chambers were within normal
limits. The next step performed was a surgical implantation
of an artificial biventricular pacemaker under general
anesthesia. The first active electrode was inserted through
the basilic vein to the right ventricle and eventually placed
in the septal part of right ventricular outflow tract, whereas
the second active electrode was inserted through the sub-
clavian vein and placed in the right atrium. The dual-
chamber pacemaker IDENTITY ADxXL DR from St. Jude
Medical was successfully installed and programmed. Con-
trol electrocardiogram revealed a pacemaker rhythm ofFigure 3 Standard ECG showing complete atrio-ventricular block. Atri
42 bpm, narrow QRS (black square). Paper speed 50 mm/s.75 bpm with ventricular stimulation controlled by the na-
tive sinus rhythm.
During the next 6 months, a progressive deterioration
of the left ventricle was observed. In the performed
echocardiogram, features of dilated cardiomyopathy
were revealed. The picture of the heart suggested left
ventricle noncompaction (LVNC), which is a congenital
genetic developmental defect of heart muscle. At that
time the boy had an implanted cardioverter – defibrilla-
tor with resynchronising stimulation. The prognosis was
at that time also uncertain.
At the age of 17, the rGH therapy was discontinued
due to a deceleration of height velocity - with a final
obtained height of 163 cm. Unfortunately, due to multi-
organ insufficiency and inflammation, the patient died at
the age of 18 years.
Molecular analysis of mitochondrial DNA was performed
with total DNA isolated from the patient’s peripheral blood.
For molecular analysis, we obtained two separate blood
samples collected at a two year interval. This allowed us to
compare how genetic disturbances changed, if they did at
all, with the progression of disease. 20 ng of DNA was used
for amplification of specific PCR products representing
almost the whole mtDNA molecule (Figure 4A). Con-
trol reactions were performed using a DNA template from
a healthy individual. Additional, smaller PCR products
after gel electrophoresis were observed that indicated
the presence of a deletion (Figure 4B). The analysis of
sequences of the small product mapped the deletion to
the region between nucleotides 6340 and 14 003 on theal rhythm (white circle) of 70 bpm and ventricular escape rhythm of
Figure 4 (See legend on next page.)
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Figure 4 A,B,C. Results of molecular analysis of patient’s mitochondrial DNA. A - Schematic localization of PCR primers used for the detection of
deletion in mtDNA; B - Result of Long-Range PCR detection of mitochondrial deletion, numbers represent samples from different patients
suspected for KSS, numbers 46 and 47 represent two samples from presented patient, L indicates molecular weight ladder (GelPilot High Range
Ladder, QIAGEN); C - Schematic localization of detected mtDNA deletion.
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(7663 bp) removes almost half of the mtDNA molecule
along with genes which encode critical proteins in the
mitochondrial electron transport chain: cytochrome c
oxydase, NADH dehydrogenase, ATP synthase and 8
tRNAs. Such a dramatic rearrangement of mitochon-
drial DNA must have a significant impact on mitochon-
drial function, but the influence of this deletion on
clinical symptoms and the severity of the disease also
depends on the level of heteroplasmy.
Quantitative analysis of the heteroplasmy level was
performed by Real-Time PCR technique. 20 ng of total
DNA was analyzed using QuantiTect SYBR Green PCR
Kit (Qiagen) on a Mastercycler ep realplex machine
(Eppendorf) and four specially designed primer sets. All
reactions were done in triplicate. Melting curve analysis
was added at the end of all reactions. Relative expression
ratios of mtDNA levels were calculated using the ΔCT
method. As a control of the total mtDNA level, we
analyzed the DNA of five healthy individuals, using the
same primers as for the patient. Amplification results were
presented as a relative expression towards the expression
level of a housekeeping, nuclear gene - GAPDH. TheFigure 5 Chronologic occurrence of clinical symptoms in presented bresults of this analysis revealed that the total level of
mtDNA in the patient’s blood was comparable to the nor-
mal mtDNA level in the first, older DNA sample, but sig-
nificantly higher (2.6×) in the second sample.
Next, we tested the heteroplasmy level, analyzing in
separate reactions only normal, non-deleted mtDNA
molecules, or only molecules with the deletion. A com-
parison of the results of these two reactions revealed
that mtDNA molecules with the deletion comprise about
3% of the total mtDNA pool in the patient’s blood.
The presented patient is a case with a typical symptom
sequence of KSS (Figure 5) and with a big, novel dele-
tion in mtDNA.
This observation, with changing total mtDNA, fits well
with the standard pattern of genetic rearrangements dur-
ing the course of mitochondrial cytopathies. It was
demonstrated that in patients with single deletions at high
heteroplasmy levels the amount of mitochondria within
the cells was nearly doubled [7]. Therefore, even consider-
ably reduced levels of enzyme activity can be compensated
for by increased amounts of mitochondria. In another in-
vestigation, an approximately nine-fold amplification of
mtDNA in muscle was detected [8]. Other reports alsooy.
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and normal mtDNA in the course of KSS [9].
The low percentage of the deleted form of mtDNA
compared to total mtDNA was not surprising, because
the level of mutated mtDNA in blood is usually very low
and sometimes undetectable [5]. The observed level of
mutated mtDNA in blood lymphocytes does not correl-
ate with the severity of observed clinical symptoms of
the disease. It is also likely that the level of mutated
mtDNA in other tissues was much higher, but that was
impossible for us to test because we lacked a muscle
biopsy specimen for analysis.
The boy had the classic triad, plus the cardiac conduc-
tion defect. The dominant disturbances at the beginning
of disease manifestation were ophthalmologic, then
endocrinologic. With the development of the disease, the
cardiac complications became very severe, subsequently
leading to a life-threatening state.
Most cases of KSS (like the presented patient) and
other mitochondrial cytopathies are first diagnosed as
various endocrine disorders and the diagnosis of KSS is
later established after several years [10,11].
Endocrinologic pathologies in the presented patient were
as follows: GH deficiency, hypothyroidism and impaired
endocrine function of the pancreas. At the beginning of
rGH treatment the prognosis concerning the therapy re-
sponse was uncertain. The improvement of height velocity
during rGH therapy was very satisfactory, and exceptional
if compared to other children treated with KSS in our
clinic. After glucose metabolism became impaired and the
dose of rGH was reduced, the patient still accelerated on
his growth chart. This means that the growth signal was
transduced properly, despite the main disease. The large
mtDNA deletion and resultant metabolic defects had no
impact on treatment response to rGH.
The cardiac manifestations of KSS are the most import-
ant aspects of the disease for determining the prognosis
[12]. Manifestations of cardiac disease occur in 57% of
patients with Kearns-Sayre Syndrome, including syncopal
attacks, heart failure and cardiac arrest [13]. Patients with
KSS typically develop cardiac conduction defects that pro-
gress to complete heart block and then manifest clinically
as heart failure, syncope or sudden death. Cases described
in the literature show the progressive course of life-
threatening conduction abnormalities in KSS [14]. Patients
who do not have conduction disturbances should be
closely monitored for the development of conduction
defects. In all patients with mtDNA mutations, not just
KSS patients, mortality among those with no cardiac dis-
ease is 26% vs. 71% in patients with cardiomyopathy [15].
Pacemakers are recommended for all patients with neuro-
muscular diseases (including KSS) who have developed
atrioventricular (AV) block, however, prophylactic pace-
maker placement prior to the development of third-degreeor advanced second-degree AV block is discussed with
patients and families as well [16]. Based on the Inter-
national Society of Heart and Lung Transplantation data-
base, 6 patients who received heart transplantation
between 1990 and 2003 had a diagnosis of myopathy due
to a mitochondrial pathology [17].
The question is whether rGH treatment could have an
impact on the cardiological complications in the patient.
GH, both in excess and in deficient states can be
associated with increased cardiovascular disturbances. Ex-
posure to high GH levels causes the hypertrophy of
cardiac myocyte [18]. Patients with GH oversecretion de-
velop acromegalic cardiomyopathy, biventricular hyper-
trophy and eventual heart failure [19]. Dysrhythmias are
also observed in acromegaly. Most common are ventricu-
lar arhythmias, like premature ventricular beats, ventricu-
lar bigeminy and ventricular tachycardia [20]. In GH
deficiency an increased risk of ischemic heart disease is
described [21]. GH deficiency results in a change in body
composition, bone mineral density, an altered lipid profile,
and decreased muscle mass. Therefore the proper balance
within the GH and IGF-1 axis is necessary for maintaining
normal cardiac function.
The presented patient had growth hormone deficiency
and was treated with substitution doses of rGH. The
IGF-1 concentration during rGH administration was
within the normal range throughout the entire period of
treatment. Therefore, the proper homeostasis of GH and
IGF-1 axis was maintained. There is no evidence that
rGH could have had a negative impact on cardiac func-
tion in this boy. It is rather to be suspected that treat-
ment with rGH could even have a beneficial influence
on the heart. There are some studies that show a posi-
tive influence of rGH on myocardium, also in dilated
cardiomyopathy. GH can improve left ventricle structure
and cardiac output, leading to a better hemodynamic
profile of the heart [22,23].
Conclusions
The presented case shows the classical clinical characteristics
of Kearns-Sayre Syndrome. The urgent and rapid mani-
festation of severe cardiac dysfunction emphasizes the
necessity of careful cardiological follow-up in KSS. The
response to rGH in KSS is somewhat unpredictable,
similarly to cardiac dysfunction, and there is no proof
that rGH treatment contributes to the onset of the con-
duction block.Consent
Written informed consent was obtained from the mother
of the patient for publication of this case report and any
accompanying images. A copy of the written consent is
available for review by the Series Editor of this journal.
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